<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23382">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01914913</url>
  </required_header>
  <id_info>
    <org_study_id>CSCC/BMRP/2013//01</org_study_id>
    <nct_id>NCT01914913</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Safety and Efficacy of Stem Cell Therapy in Retinitis Pigmentosa</brief_title>
  <official_title>An Open Labeled Clinical Study to Evaluate the Safety and Efficacy Mesenchymal Stem Cell in Retinitis Pigmentosa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chaitanya Hospital, Pune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chaitanya Hospital, Pune</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinitis pigmentosa is an eye disease in which there is damage to the retina. The retina is
      the layer of tissue at the back of the inner eye that converts light images to nerve signals
      and sends them to the brain.Stem cell therapy is used as therapy for this condition .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will involve about 8 visits over 1Â½ years .Each participant will be enrolled in
      study as per inclusion and exclusion criteria .Informed consent will be taken from subject
      before including in study.  Subject will be underwent for specific tests of the
      participant's vision and health. These visits may include visual exams, blood draw for
      laboratory testing, brief medical history and exam, and occasionally a questionnaire
      (survey), in addition to the visit for the surgical procedures. The primary outcome for this
      study will be a visual acuity score after one year of stem cell therapy .

      Follow-up visits  will be required regularly to determine  the effectiveness of stem cell
      therapy in  RP.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>visual acuity</measure>
    <time_frame>1 YEAR</time_frame>
    <safety_issue>No</safety_issue>
    <description>Electronic Visual Acuity (EVA) technology</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>transfer of Mesenchymal Stem Cell ( MSCs )</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Transfer of Mesenchymal Stem Cell ( MSCs )</intervention_name>
    <description>Intervention therapy , Total 6 doses ,in 30 days ,in 7days interval ,transfer of Bone marrow derived Mesenchymal Stem Cell ( MSCs ).</description>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  Diagnosis of retinitis pigmentosa

          -  willingness to undergo Bone marrow and umbilical cord derived Mesenchymal stem cell
             transplantation.

          -  To give an informed consent as well as sign the required Informed Consent Form (ICF)
             for the study.

          -  willingness to regularly visit the hospital / clinic for follow up during the follow
             up period / on prior agreed time points as per the protocol.

        Exclusion Criteria:

          -  Positive test results for HIV and AIDS complex ,HCV (hepatitis C virus ), HbsAg and
             Syphilis

          -  Women who are pregnant or lactating

          -  Complications of diabetic retinopathy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANANT E BAGUL, MS ORTHO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaitanya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sachin P Jamadar, D.Ortho</last_name>
    <phone>918888788880</phone>
    <email>sac2751982@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Smita S Bhoyar, B.A.M.S.PGCR</last_name>
    <phone>9372620569</phone>
    <email>drsmitabhoyar@rediff.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaitanya Hospital</name>
      <address>
        <city>Pune,</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sachin P Jamadar, D ORTHO</last_name>
      <phone>+918888788880</phone>
      <email>sac2751982@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anant E Bagul, MS,Ortho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>July 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chaitanya Hospital, Pune</investigator_affiliation>
    <investigator_full_name>Dr. Sachin Jamadar</investigator_full_name>
    <investigator_title>Co -investigator</investigator_title>
  </responsible_party>
  <keyword>retinitis pigmentosa</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
